ProQR Therapeutics (PRQR) Accumulated Expenses (2021 - 2022)

ProQR Therapeutics' Accumulated Expenses history spans 2 years, with the latest figure at $8.9 million for Q4 2022.

  • For Q4 2022, Accumulated Expenses fell 28.0% year-over-year to $8.9 million; the TTM value through Dec 2022 reached $8.9 million, down 28.0%, while the annual FY2022 figure was $9.2 million, 28.1% down from the prior year.
  • Accumulated Expenses for Q4 2022 was $8.9 million at ProQR Therapeutics, down from $12.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $12.3 million in Q4 2021 and bottomed at $8.9 million in Q4 2022.